美國的多發性骨髓瘤市場:各類藥物，各疾病類型，各流通管道，各地區，機會，預測，2018年～2032年

美國多發性骨髓瘤市場規模預計將從 2024 年的 80.1 億美元增長至 2032 年的 122.9 億美元，預測期內（2025-2032 年）的複合年增長率為 5.50%。多發性骨髓瘤發生率的上升和早期診斷的增多，正在擴大尋求治療的患者群體。加速審批等監管激勵措施正在刺激研發，加速新型療法的市場進入。免疫療法（尤其是抗 CD38 單株抗體）的採用率激增，改變了治療偏好。

例如，美國癌症協會預測，到2025年，美國將新增約36,110例多發性骨髓瘤病例（其中男性20,030例，女性16,080例）。預計死亡人數約12,030人，其中男性6,540人，女性5,490人。美國患者一生中罹患多發性骨髓瘤的風險估計不到1%，大約每108名男性中就有1人罹患，每133名女性中就有1人罹患。這種癌症主要影響老年人，不到1%的病例發生在35歲之前。大多數確診患者至少65歲，平均確診年齡為69歲。

本報告提供美國的多發性骨髓瘤市場相關調查，提供市場概要，以及各類藥物，各疾病類型，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 美國的多發性骨髓瘤市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
  • 各類藥物
    • 免疫調節劑
    • 蛋白梅體抑制劑
    • 抗CD38單株抗體
    • 烷化劑
    • 其他
  • 各疾病類型
    • 活動性多發性骨髓瘤
    • 冒煙型多發性骨髓瘤
  • 各流通管道
    • 醫院藥局
    • 零售藥局和藥妝店
    • 線上藥局
  • 各地區
    • 西北部
    • 南部
    • 西部
    • 中西部
  • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
• 2024年的市場地圖分析

第6章 需求供給分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

• 市場促進因素
• 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

• 法規當局的認證
• 臨床試驗

第14章 專利的形勢

第15章 案例研究

第16章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Amgen, Inc.
  • AbbVie Inc.
  • Teva Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Janssen United States Services, LLC
  • Sanofi S.A.
  • Ono Pharmaceutical Co., Ltd.
  • Genentech, Inc.

第17章 策略性建議

第18章 關於調查公司·免責聲明

United States multiple myeloma market is projected to witness a CAGR of 5.50% during the forecast period 2025-2032, growing from USD 8.01 billion in 2024 to USD 12.29 billion in 2032. Rising incidence of multiple myeloma and early diagnosis are expanding the treatment-seeking patient base. Regulatory incentives like accelerated approvals are encouraging R&D and speeding market entry of novel therapies. Surging adoption of immunotherapies, especially Anti-CD38 monoclonal antibodies, is reshaping treatment preferences.

For instance, the American Cancer Society projects that in 2025, there will be approximately 36,110 new diagnoses of multiple myeloma in the United States, comprising 20,030 men and 16,080 women. It is anticipated that around 12,030 fatalities will occur, with 6,540 in men and 5,490 in women. The lifetime risk of developing multiple myeloma in the United States is estimated to be less than 1%, translating to about 1 in 108 for men and 1 in 133 for women; however, individual risk may vary based on specific risk factors. This type of cancer predominantly affects older adults, with less than 1% of cases occurring in individuals under 35 years of age. The majority of those diagnosed are at least 65 years old, with the average age at diagnosis being 69.

Rising Incidences of Multiple Myeloma and Expanding Diagnostic Capabilities

The growing incidence of multiple myeloma in the United States is significantly fueling demand for effective therapeutic options. As one of the most common forms of blood cancer, multiple myeloma accounts for roughly 1.8% of all cancer diagnoses in the country. Early diagnosis and disease monitoring have improved owing to advancements in imaging techniques and laboratory diagnostics such as serum protein electrophoresis and free light chain assays. Moreover, awareness campaigns by organizations like the Multiple Myeloma Research Foundation have boosted early detection rates, allowing for the timely initiation of treatment. This has increased the need for targeted and combination therapies to improve patient survival. To meet rising demand, pharmaceutical companies are investing in robust drug pipelines. For instance, in April 2024, Bristol Myers Squibb announced US FDA approval for a subcutaneous version of Abecma, a CAR-T cell therapy, offering faster administration for relapsed or refractory multiple myeloma.

Robust Pipeline and Accelerated Regulatory Approvals Propel Market Growth

The United States multiple myeloma therapeutics landscape is evolving rapidly with continuous pipeline expansion and an increase in expedited drug approvals by the U.S. Food and Drug Administration (FDA). Due to the high unmet clinical need and the progressive nature of the disease, the FDA offers designations like Fast Track, Breakthrough Therapy, and Orphan Drug to promote quicker access to innovative treatments. This favorable regulatory environment has encouraged major players to develop and commercialize novel agents targeting disease-specific pathways, such as BCMA (B-cell maturation antigen). Pharmaceutical giants are also leveraging biologics, cell therapies, and bispecific antibodies to address treatment-resistant cases. In August 2023, the FDA granted accelerated approval to Johnson & Johnson's bispecific antibody Talvey (talquetamab-tgvs), a first-in-class GPRC5D-targeting therapy for relapsed or refractory multiple myeloma. This milestone illustrates how regulatory incentives are reducing development timelines, bolstering investment in R&D, and increasing the number of approved therapies on the U.S. market.

Growing Preference for Targeted Immunotherapies and Monoclonal Antibodies

Segment-specific growth in the U.S. multiple myeloma market is being significantly driven by rising adoption of targeted immunotherapies, particularly Anti-CD38 monoclonal antibodies such as daratumumab and isatuximab. These therapies have demonstrated superior efficacy over conventional treatment regimens by targeting specific antigens on myeloma cells while sparing healthy tissues. Anti-CD38 agents are increasingly used in frontline therapy settings and in combination with other classes like proteasome inhibitors and immunomodulatory drugs. The growing clinician and patient preference for these biologics is fueled by their proven survival benefits, fewer adverse events, and extended duration of response. Additionally, pharma companies are actively investing in next-generation monoclonal antibodies with enhanced tumor cell-killing properties. For example, in September 2024, the US Food and Drug Administration (FDA) granted approval for Sarclisa (isatuximab) to be used in conjunction with bortezomib, lenalidomide, and dexamethasone (VRd) as a primary treatment option for adult patients diagnosed with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplants (ASCT). Sarclisa represents the first anti-CD38 therapy that, when combined with the standard VRd regimen, has been shown to significantly decrease the risk of disease progression or mortality (by 40%) compared to VRd alone in patients with NDMM who are not eligible for transplants.

Future Market Scenario (2025-2032F)

The United States multiple myeloma market is poised for strong growth in the coming years due to rising disease incidence, increased awareness, and advances in diagnostic and therapeutic technologies. With a rapidly aging population and improved early detection, the patient pool is expected to expand, driving demand for targeted therapies, immunomodulators, and monoclonal antibodies. Innovations such as CAR-T cell therapies and bispecific antibodies are revolutionizing treatment approaches, offering better survival outcomes and improved quality of life. Additionally, the favorable regulatory environment, coupled with strong investments in research and development, is accelerating drug approvals. As pharmaceutical companies focus on the combination of regimens and personalized medicine, the market is expected to witness robust expansion and continuous clinical innovation.

Key Players Landscape and Outlook

The key players in the market are significantly investing in developing multiple myeloma and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, on November 6, 2024, Nanjing Leads Biolabs Co., Ltd. announced that LBL-034, a humanized bispecific T-cell engaging antibody aimed at GPRC5D and CD3 for the treatment of multiple myeloma, has been granted Orphan Drug Designation (ODD) by the U.S. FDA.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Multiple Myeloma Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Immunomodulators
    • 5.2.1.2. Proteasome Inhibitor
    • 5.2.1.3. Anti-CD38 Monoclonal Antibody
    • 5.2.1.4. Alkylating Agents
    • 5.2.1.5. Others
  • 5.2.2. By Disease Type
    • 5.2.2.1. Active Multiple Myeloma
    • 5.2.2.2. Smoldering Multiple Myeloma
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies and Drug Stores
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. Northwest
    • 5.2.4.2. South
    • 5.2.4.3. West
    • 5.2.4.4. Midwest
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Class
  • 5.3.2. By Disease Type
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis AG
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Takeda Pharmaceutical Company Limited
  • 16.3.3. Amgen, Inc.
  • 16.3.4. AbbVie Inc.
  • 16.3.5. Teva Pharmaceuticals, Inc.
  • 16.3.6. Bristol-Myers Squibb Company
  • 16.3.7. Janssen United States Services, LLC
  • 16.3.8. Sanofi S.A.
  • 16.3.9. Ono Pharmaceutical Co., Ltd.
  • 16.3.10. Genentech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Multiple Myeloma Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Multiple Myeloma Market Share (%), By Drug Class, 2018-2032F
• Figure 3. United States Multiple Myeloma Market Share (%), By Disease Type, 2018-2032F
• Figure 4. United States Multiple Myeloma Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. United States Multiple Myeloma Market Share (%), By Region, 2018-2032F
• Figure 6. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 7. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024